# CRG-023

Source: https://onco.cc/drugs/crg-023/  
OnCo record `crg-023` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CRG-023 is an experimental autologous tri-specific CAR T-cell therapy from CARGO Therapeutics, in preclinical development for large B-cell lymphoma; its current status is not stated.

## Summary

CRG-023 is an autologous tri-specific CAR T-cell therapy from CARGO Therapeutics. T cells carrying three separate CARs against CD19, CD20 and CD22 expressed from one lentiviral vector, each with its own co-stimulatory domain, including a CD2 co-stimulatory domain. Its furthest stage is preclinical development, for large B-cell lymphoma. No clinical trial naming it is registered on ClinicalTrials.gov. FDA allowed the IND in January 2025; in March 2025 the board suspended various development efforts and the company was later acquired. No trial registered. It has not been shown to work in people.

## Fields

- Kind: Treatment
- Status: preclinical
- Last checked: 2026-11-03
- Tags: pipeline
- Code: CRG-023
- Modality: Autologous tri-specific CAR T-cell therapy
- Mechanism: T cells carrying three separate CARs against CD19, CD20 and CD22 expressed from one lentiviral vector, each with its own co-stimulatory domain, including a CD2 co-stimulatory domain.

## Sources

- CARGO Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1966494/000095017025066940/crgx-20250331.htm
- CARGO Therapeutics: sec.gov: https://www.sec.gov/Archives/edgar/data/1966494/000095017025066940/crgx-20250331.htm

## Connected records

- targets: [CD19](https://onco.cc/targets/cd19/), [CD20](https://onco.cc/targets/cd20/), [CD22](https://onco.cc/targets/cd22/)
- companies: [CARGO Therapeutics](https://onco.cc/companies/cargo-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/crg-023.json